MARKET

HROWM

HROWM

Harrow Health Inc
NASDAQ
26.08
-0.47
-1.77%
Closed 15:11 04/04 EDT
OPEN
26.55
PREV CLOSE
26.55
HIGH
26.55
LOW
26.02
VOLUME
3.16K
TURNOVER
--
52 WEEK HIGH
27.70
52 WEEK LOW
23.50
MARKET CAP
--
P/E (TTM)
-53.1919
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at HROWM last week (0324-0328)?
Weekly Report · 6d ago
Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)
Seeking Alpha · 03/29 20:30
Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp
Seeking Alpha · 03/28 17:39
Harrow Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 03/27 22:28
Based on the provided financial report articles, I generated the title for the article: **"Eton Pharmaceuticals, Inc. (0001360214) Annual Report for the Fiscal Year Ended December 31, 2024"** Please note that the title may not be exact, as the provided text appears to be a financial report with various sections and data. If you'd like me to generate a more specific title based on the content, please let me know!
Press release · 03/27 20:31
HARROW INC: Q4 EPS $0.40
Reuters · 03/27 20:01
HARROW ANNOUNCES FOURTH-QUARTER AND YEAR-END 2024 AUDITED FINANCIAL RESULTS
Reuters · 03/27 20:01
HARROW INC - TRIESENCE ELIGIBLE FOR SEPARATE REIMBURSEMENT IN ASC AND HOPD SETTINGS FROM APRIL 2025
Reuters · 03/24 11:02
More
About HROWM
More
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Recently
Symbol
Price
%Change

Webull offers Harrow Inc stock information, including NASDAQ: HROWM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HROWM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HROWM stock methods without spending real money on the virtual paper trading platform.